Oncology-New York最新文献_第3页

2025 Report on the Mantle Cell Lymphoma Scientific Consortium and Workshop Hosted by the Lymphoma Research Foundation. 2025年由淋巴瘤研究基金会主办的套细胞淋巴瘤科学联盟和研讨会报告。

IF 2 4区医学

Oncology-New York Pub Date : 2026-02-10 DOI: 10.46883/2026.25921063

Lymphoma Research Foundation Lymphoma Research Foundation

{"title":"2025 Report on the Mantle Cell Lymphoma Scientific Consortium and Workshop Hosted by the Lymphoma Research Foundation.","authors":"Lymphoma Research Foundation Lymphoma Research Foundation","doi":"10.46883/2026.25921063","DOIUrl":"10.46883/2026.25921063","url":null,"abstract":"Mantle cell lymphoma (MCL) is a rare, aggressive form of non-Hodgkin lymphoma that arises from cells within the mantle zone (the outer ring of lymphocytes surrounding the center of a lymphatic nodule). Recent treatment advances, such as the introduction of Bruton tyrosine kinase inhibitors and chimeric antigen receptor T-cell therapies, have improved outcomes for many patients. Development of resistance is common, though, and relapse rates are high in MCL. The molecular mechanisms that contribute to resistance remain unclear, and the clinical heterogeneity of MCL can make it difficult to predict how patients will respond to treatment. Thus, there remains an urgent need for continued research on the molecular drivers of MCL pathogenesis, mechanisms of resistance, and novel strategies for targeting these pathways to improve outcomes for patients across the spectrum of disease. In April 2025, researchers gathered for the Lymphoma Research Foundation's 21st Mantle Cell Lymphoma Scientific Consortium and Workshop to discuss recent developments in the characterization and treatment of MCL. This report, which includes a summary of each presentation, aims to review the findings presented at the workshop and highlight new opportunities and unanswered questions in the care of patients with MCL, paving the way for novel treatments to improve outcomes and experiences in the years to come.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"40 1","pages":"16-32"},"PeriodicalIF":2.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies. 人工智能在姑息肿瘤学中的作用：聚焦于血液恶性肿瘤。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-12-01 DOI: 10.46883/2025.25921057

Ram Prakash Thirugnanasambandam, Ariana Bauer, Christopher D'Angelo

{"title":"The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies.","authors":"Ram Prakash Thirugnanasambandam, Ariana Bauer, Christopher D'Angelo","doi":"10.46883/2025.25921057","DOIUrl":"10.46883/2025.25921057","url":null,"abstract":"Artificial intelligence (AI) is transforming health care by enhancing diagnostics, treatment planning, and patient monitoring. In palliative oncology, particularly for hematologic malignancies, AI has shown promise in improving symptom management, prognostication, and personalized care. AI-driven models utilizing electronic health records, wearable devices, and predictive analytics aid in the early detection of symptoms, optimization of pain management, and streamlining of clinical decision-making. Machine learning algorithms have also enhanced risk stratification in leukemia, lymphoma, and multiple myeloma by integrating genomic data, imaging, and treatment responses to refine prognostic models. Additionally, AI-powered tools support cancer survivorship by monitoring late-treatment effects and aiding end-of-life care through predictive analytics for timely palliative interventions. Despite these advancements, challenges remain, including data bias, ethical concerns, and the need for prospective validation in clinical settings. Addressing these limitations will be crucial for fully integrating AI into palliative oncology and hematologic malignancy care.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 10","pages":"468-478"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145726611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers. 妇科癌症临床试验可获得性与疾病分布的差异

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-12-01 DOI: 10.46883/2025.25921058

Andrea I Nañez Md, Maria A Velez, Mae Zakhour Md, Edward B Garon

{"title":"Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers.","authors":"Andrea I Nañez Md, Maria A Velez, Mae Zakhour Md, Edward B Garon","doi":"10.46883/2025.25921058","DOIUrl":"10.46883/2025.25921058","url":null,"abstract":"Objective: Given disparities in incidence and outcomes among racial and ethnic groups, and differences in patient characteristics among the 3 main types of gynecologic cancer, we examined whether clinical trial availability at a large, high-enrolling National Cancer Institute-designated Comprehensive Cancer Center reflects the clinical volume of each cancer in the catchment area. We also assessed whether the patients who consented to the trials reflected the racial and ethnic distribution of each cancer type.Methods: Patients who consented to ovarian, uterine, and cervical cancer clinical trials at the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, from 2013 through 2018 were included. Clinical trial and patient-level data were collected. Los Angeles County cancer incidence data were used to represent disease burden in the catchment area. χ-Square and Fisher exact tests were used to compare proportions.Results: Twenty-four gynecologic oncology clinical trials were identified: 16 (67%) ovarian, 5 (21%) uterine, and 3 (12%) cervical cancer trials. Compared with corresponding county incidence rates, respectively, the proportion of patients with ovarian (82% vs 25%), uterine (9% vs 59%), or cervical (9% vs 6%) cancer who consented for clinical trials differed significantly ( P < .001). The racial/ethnic distribution of patients also differed for ovarian ( P < .001) and cervical cancer trials ( P = .005). Patients who were Black or Asian were underrepresented in ovarian and cervical cancer trials; Hispanic patients were underrepresented in ovarian trials.Conclusions: The distribution of clinical trials and patients who consented did not reflect the incidence or racial and ethnic makeup of gynecologic cancers in the catchment area. Greater efforts are needed to align trial availability and enrollment with disease burden and population diversity.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 10","pages":"456-462"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145726685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva. 揭示外阴近端上皮样肉瘤的复杂性。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-10-21 DOI: 10.46883/2025.25921054

Fatimah M Kaabi Mbbs, Chaker Zaidi Md PhD, Fatimah Abdullah Alessa Mbbs, Yasser Sorour Md PhD

{"title":"Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva.","authors":"Fatimah M Kaabi Mbbs, Chaker Zaidi Md PhD, Fatimah Abdullah Alessa Mbbs, Yasser Sorour Md PhD","doi":"10.46883/2025.25921054","DOIUrl":"10.46883/2025.25921054","url":null,"abstract":"Purpose: To present a rare case of proximal-type epithelioid sarcoma (PES) of the vulva and highlight the importance of a multidisciplinary approach in its diagnosis and treatment, especially in the context of SMARCB1 loss.Methods: A 41-year-old woman presented with a painless mass in the right labia majora. An MRI, PET/CT, histopathology, and immunohistochemistry confirmed the diagnosis of PES with loss of SMARCB1 expression. The patient underwent wide local excision followed by re-excision and inguinal lymphadenectomy. Adjuvant radiotherapy was initiated but discontinued at 46 Gy due to grade 2 skin reactions and wound dehiscence.Results: Posttreatment PET/CT imaging posed challenges in distinguishing between recurrence and radiation-induced changes. Despite these challenges, the patient remained disease free during the 2-year follow-up period. This case underscores the diagnostic and therapeutic complexities involved in treating PES, particularly in sensitive anatomical regions such as the vulva. The loss of SMARCB1 served as a key molecular marker guiding diagnosis and therapeutic decisions.Conclusion: The case underscores the importance of a comprehensive, individualized treatment approach, including surgery, radiotherapy, and advanced imaging, for managing rare malignancies such as vulvar PES.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 9","pages":"394-399"},"PeriodicalIF":1.8,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145422975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era. pet适应时代晚期经典霍奇金淋巴瘤的治疗进展。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-10-21 DOI: 10.46883/2025.25921053

Wael Abdulla Moh Khair Md

{"title":"Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era.","authors":"Wael Abdulla Moh Khair Md","doi":"10.46883/2025.25921053","DOIUrl":"10.46883/2025.25921053","url":null,"abstract":"Interim fluorodeoxyglucose (FDG)-PET is currently the most used predictor of early response to treatment in advanced-stage Hodgkin lymphoma. Patients with a negative PET after 2 cycles of chemotherapy (PET2) have a better treatment outcome than their counterparts. The objective of this review was to assess how PET-adapted treatment approaches have enhanced the management of advanced-stage Hodgkin lymphoma by adapting treatment according to initial response. PubMed, Web of Science, ScienceDirect, Google Scholar, Scopus, and the Cochrane Library were systematically searched using randomized controlled trials, phase 2/3 clinical trials, and systematic reviews between 2000 and 2024. Keywords used were \"Hodgkin lymphoma,\" \"PET-adapted treatment,\" \"ABVD,\" \"BEACOPP,\" \"interim PET,\" and \"treatment escalation/de-escalation.\" PET-adapted treatment strategies decrease PET2-negative patient treatment, decreasing adverse effects with no reduction in effectiveness, as evidenced by the RATHL, AHL2011, and HD18 trials. In PET2-positive patients, trials such as SWOG S0816 and HD0607 prove that the early intensification of treatment improves survival. Novel treatments, such as brentuximab vedotin and nivolumab, are promising options.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 9","pages":"424-430"},"PeriodicalIF":1.8,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145423497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1-Positive Metastatic NSCLC. Trabedersen （OT-101）联合Pembrolizumab治疗新诊断的pd - l1阳性转移性NSCLC。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-10-21 DOI: 10.46883/2025.25921056

Omar K Abughanimeh Mbbs, Anthony E Maida Iii PhD Ma Mba, Sanjive Qazi PhD, Kate-Lynn Muir DO, Bhavina Sharma, Lynette Smith PhD, Apar Kishor Ganti

引用次数: 0

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology. 趋同和发散信号通路在癌症：自适应精确肿瘤学的双轴模型。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-10-21 DOI: 10.46883/2025.25921052

Aliasgar Shahiwala PhD

{"title":"Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology.","authors":"Aliasgar Shahiwala PhD","doi":"10.46883/2025.25921052","DOIUrl":"10.46883/2025.25921052","url":null,"abstract":"Despite significant advances in cancer research, the complexity of signaling pathways remains a major challenge in precision oncology. Tumors harbor a diverse array of genetic alterations; however, these often converge onto a limited set of core signaling pathways, notably RAS/RAF/MEK/ERK (MAPK), PI3K/AKT/mTOR (PAM), and Wnt/β-catenin. Concurrently, these pathways diverge extensively downstream, driving therapeutic resistance through mechanisms such as epithelial-mesenchymal transition, immune evasion, and metabolic reprogramming. Unlike previous literature that largely provides descriptive accounts of pathway alterations, this review uniquely synthesizes convergent and divergent signaling into a clinically actionable diagnostic and therapeutic framework. It critically assesses current precision oncology strategies, identifies gaps, and proposes a dual-axis model that integrates static genomic profiling with dynamic signaling evolution to inform precision therapy. By highlighting opportunities for combination therapy informed by pathway interdependencies and adaptive resistance mechanisms, this perspective provides novel clinical insights and tangible directions for future research in overcoming resistance in cancer treatment.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 9","pages":"386-393"},"PeriodicalIF":1.8,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145423477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Late Hepatic Recurrence From Granulosa Cell Tumor: A Case Report. 肝颗粒细胞瘤晚期复发1例。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-10-21 DOI: 10.46883/2025.25921055

Prosper Akankwasa Mbbs, Jackson Kakooza Mbbs, Aisha Abdullahi Ahmed Mbbs, Catherine R Lewis

引用次数: 0

Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic Features. 一例具有非典型组织病理特征的罕见胶质母细胞瘤的分子特征。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-09-15 DOI: 10.46883/2025.25921050

Nanuli Gvazava, Tolga Tuncer, Wei Zhang, Anup Kasi, Uma Bhoot

引用次数: 0

Improving Leukoplakia Follow-Up: Information Leaflets, Habit Cessation Counseling. 改善白斑随访：信息单张，戒烟辅导。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-09-15 DOI: 10.46883/2025.25921051

Shaila Mulki, Seema Mavinapalla, Supriya Hulimane, Elizabeth Sojan, Deviprasad Nooji, Vidya Gowdappa Doddawad

{"title":"Improving Leukoplakia Follow-Up: Information Leaflets, Habit Cessation Counseling.","authors":"Shaila Mulki, Seema Mavinapalla, Supriya Hulimane, Elizabeth Sojan, Deviprasad Nooji, Vidya Gowdappa Doddawad","doi":"10.46883/2025.25921051","DOIUrl":"10.46883/2025.25921051","url":null,"abstract":"Background: The rising incidence of oral cancer necessitates widespread implementation of preventive measures, particularly in resource-challenged settings where visual examination and patient education are more feasible. Addressing the reluctance of patients clinically diagnosed with leukoplakia and reinforcing the importance of follow-up care is imperative. The study aims to assess the impact of patient information leaflets (PILs) and habit cessation counseling (HCC) on clinically diagnosed patients with leukoplakia.Materials and methods: The study included 60 clinically diagnosed cases of leukoplakia and was divided into 3 groups (20 participants each). Group 1 received an expert-designed PIL, group 2 had HCC, and group 3 received both PILs and HCC. All groups underwent follow-up assessments, including lesion reexamination and a structured questionnaire.Results: Group 3 demonstrated the highest level of understanding and application of the information, as reflected in both their attitude and practice toward their habits, and group 2 did better than group 1.Conclusion: The combination of a PIL and an HCC can effectively support reluctant patients with leukoplakia, fostering habit cessation and promoting lifestyle modifications through increased awareness.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 8","pages":"344-349"},"PeriodicalIF":1.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145151828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0